Disability in patients consulting for anxiety or mood disorders in primary care: Response to antidepressant treatment

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 605-614

  Gérard, Alain ^a   Liard, François ^b   Crochard, Anne ^c   Goni, Sylvia ^c   Millet, Bruno ^d  

^a Rue des Marronniers' Psychiatry Clinic   (France)

^b General Practice   (Spain)

^c Lundbeck   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Antidepressant; Anxiety disorder; Depression; Disability

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DULOXETINE; HYPNOTIC AGENT; MILNACIPRAN; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CONSULTATION; FAMILY LIFE; FEMALE; FOLLOW UP; FRANCE; GENERAL PRACTITIONER; GENERALIZED ANXIETY DISORDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OBSERVATIONAL STUDY; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SELF REPORT; SHEEHAN DISABILITY SCALE; SOCIAL BEHAVIOR; SOCIAL PHOBIA; TREATMENT RESPONSE;

EID: 84871483731     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S34132     Document Type: Article

References (24)

1. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc. 2009;18(1):23-33. Italian.
2. Lepine JP, Gasquet I, Kovess V, et al. Prevalence and comorbidity of psychiatric disorders in the French general population. L'Encephale. 2005;31(2):182-194. French.
3. Alonso J, Angermeyer MC, Bernert S, et al. 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;420:28-37.
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
5. Henderson S, Andrews G, Hall W. Australia's mental health: an overview of the general population survey. Aust N Z J Psychiatry. 2000;34(2):197-205.
6. Regier DA, Narrow WE, Kuhl EA, Kupfer DJ. The conceptual development of DSM-V. Am J Psychiatry. 2009;166(6):645-650.
7. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2004.
8. Ormel J, Petukhova M, Chatterji S, et al. Disability and treatment of specific mental and physical disorders across the world. Br J Psychiatry. 2008;192(5):368-375.
9. Esposito E, Wang JL, Williams JV, Patten SB. Mood and anxiety disorders, the association with presenteeism in employed members of a general population sample. Epidemiol Psichiatr Soc. 2007;16(3):231-237. Italian.
10. Lepine JP. Epidemiology, burden, and disability in depression and anxiety. J Clin Psychiatry. 2001;62 Suppl 13:4-10.
11. Alonso J, Angermeyer MC, Bernert S, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:38-46.
12. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004;26(1):13-17.
13. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70-83.
14. National Institute of Mental Health. CGI, Clinical Global Impression. In: Guy W, editor. ECDEU Assessment Manual of Psychopharmacology Review. Rockville, MD: National Institute of Mental Health; 1976.
15. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11 Suppl 3:89-95.
16. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370.
17. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety. 2005; 21(1):26-32.
18. Stamouli SS, Yfantis A, Lamboussis E, et al. Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opin Pharmacother. 2009;10(6):937-945.
19. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2008;9(4): 248-312.
20. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67-104.
21. Stein DJ, Bandelow B, Dolberg OT, Andersen HF, Baldwin DS. Anxiety symptom severity and functional recovery or relapse. Ann Clin Psychiatry. 2009;21(2):81-88.
22. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67(9):1428-1434.
23. Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol. 1997;12(1):19-29.
24. Martinez L, Gasquet I, Lenne X, et al. SSRI antidepressant prescription: compliance with recommendations? Rev Prat Med Gen. 2003;17(623):1093-1098. French.